Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.62 USD | +2.38% | +1.41% | +100.15% |
02/05 | Dyne Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
30/04 | Morgan Stanley Starts Dyne Therapeutics With Overweight Rating, $40 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+100.15% | 227.19Cr | |
+26.37% | 4.5TCr | |
-1.01% | 4.26TCr | |
+46.00% | 4.18TCr | |
-5.31% | 2.9TCr | |
+9.34% | 2.61TCr | |
-21.69% | 1.9TCr | |
+6.23% | 1.28TCr | |
+26.99% | 1.21TCr | |
-3.38% | 1.18TCr |
- Stock Market
- Equities
- DYN Stock
- News Dyne Therapeutics, Inc.
- Oppenheimer Initiates Coverage on Dyne Therapeutics With Outperform Rating, $34 Price Target